357 related articles for article (PubMed ID: 19491205)
21. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation.
Herbrecht R; Caillot D; Cordonnier C; Auvrignon A; Thiébaut A; Brethon B; Michallet M; Mahlaoui N; Bertrand Y; Preziosi P; Ruiz F; Gorin NC; Gangneux JP
J Antimicrob Chemother; 2012 Nov; 67(11):2731-8. PubMed ID: 22850692
[TBL] [Abstract][Full Text] [Related]
22. Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients.
Noskin G; Pietrelli L; Gurwith M; Bowden R
Bone Marrow Transplant; 1999 Apr; 23(7):697-703. PubMed ID: 10218847
[TBL] [Abstract][Full Text] [Related]
23. Liposomal amphotericin B does not induce nephrotoxicity or renal function impairment in premature neonates.
Manzoni P; Galletto P; Rizzollo S; Franco C; Gallo E; Antonucci R; Fanos V; Farina D
Early Hum Dev; 2012 May; 88 Suppl 2():S86-91. PubMed ID: 22633524
[TBL] [Abstract][Full Text] [Related]
24. Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B.
Krüger WH; Rüssmann B; de Wit M; Kröger N; Renges H; Sobottka I; Zander AR
Acta Haematol; 2005; 113(2):104-8. PubMed ID: 15802888
[TBL] [Abstract][Full Text] [Related]
25. Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients.
Castroagudín JF; Pontón C; Bustamante M; Otero E; Martínez J; Tomé S; Conde R; Segade FR; Delgado M; Brage A; Galbán C; Varo E
Transplant Proc; 2005 Nov; 37(9):3965-7. PubMed ID: 16386598
[TBL] [Abstract][Full Text] [Related]
26. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.
Safdar A; Rodriguez GH; Lichtiger B; Dickey BF; Kontoyiannis DP; Freireich EJ; Shpall EJ; Raad II; Kantarjian HM; Champlin RE
Cancer; 2006 Jun; 106(12):2664-71. PubMed ID: 16691620
[TBL] [Abstract][Full Text] [Related]
27. Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-than-recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections.
Hooshmand-Rad R; Reed MD; Chu A; Gotz V; Morris JA; Weinberg J; Dominguez EA
Clin Ther; 2004 Oct; 26(10):1652-62. PubMed ID: 15598482
[TBL] [Abstract][Full Text] [Related]
28. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
[TBL] [Abstract][Full Text] [Related]
29. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
[TBL] [Abstract][Full Text] [Related]
30. Study of renal safety in amphotericin B lipid complex-treated patients.
Alexander BD; Wingard JR
Clin Infect Dis; 2005 May; 40 Suppl 6():S414-21. PubMed ID: 15809928
[TBL] [Abstract][Full Text] [Related]
31. Antifungal prophylaxis with micafungin in patients treated for childhood cancer.
Kusuki S; Hashii Y; Yoshida H; Takizawa S; Sato E; Tokimasa S; Ohta H; Ozono K
Pediatr Blood Cancer; 2009 Oct; 53(4):605-9. PubMed ID: 19533659
[TBL] [Abstract][Full Text] [Related]
32. [Safety of long-term administration of conventional amphotericin B in oncology patients].
Doubek M; Mayer J; Horký D
Cas Lek Cesk; 2002 Mar; 141(5):156-9. PubMed ID: 11998223
[TBL] [Abstract][Full Text] [Related]
33. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
Cornely OA; Maertens J; Bresnik M; Ebrahimi R; Ullmann AJ; Bouza E; Heussel CP; Lortholary O; Rieger C; Boehme A; Aoun M; Horst HA; Thiebaut A; Ruhnke M; Reichert D; Vianelli N; Krause SW; Olavarria E; Herbrecht R;
Clin Infect Dis; 2007 May; 44(10):1289-97. PubMed ID: 17443465
[TBL] [Abstract][Full Text] [Related]
34. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.
Offner F; Krcmery V; Boogaerts M; Doyen C; Engelhard D; Ribaud P; Cordonnier C; de Pauw B; Durrant S; Marie JP; Moreau P; Guiot H; Samonis G; Sylvester R; Herbrecht R;
Antimicrob Agents Chemother; 2004 Dec; 48(12):4808-12. PubMed ID: 15561860
[TBL] [Abstract][Full Text] [Related]
35. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B.
Bellmann R; Cleary JD; Sterba J
Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-8. PubMed ID: 19537331
[TBL] [Abstract][Full Text] [Related]
36. Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.
Groll AH; Silling G; Young C; Schwerdtfeger R; Ostermann H; Heinz WJ; Gerss J; Kolve H; Lanvers-Kaminsky C; Vieira Pinheiro JP; Gammelin S; Cornely OA; Wuerthwein G
Antimicrob Agents Chemother; 2010 Oct; 54(10):4143-9. PubMed ID: 20660670
[TBL] [Abstract][Full Text] [Related]
37. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
[TBL] [Abstract][Full Text] [Related]
38. High-dose weekly liposomal amphotericin b antifungal prophylaxis in patients undergoing liver transplantation: a prospective phase II trial.
Giannella M; Ercolani G; Cristini F; Morelli M; Bartoletti M; Bertuzzo V; Tedeschi S; Faenza S; Puggioli C; Lewis RE; Pinna AD; Viale P
Transplantation; 2015 Apr; 99(4):848-54. PubMed ID: 25531982
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
Schonfeld W; Wang Cheng J; Tong KB; Seifeldin R
Clin Ther; 2008 May; 30(5):964-73. PubMed ID: 18555943
[TBL] [Abstract][Full Text] [Related]
40. [Clinical analysis of amphotericin B in the treatment of invasive fungal infections in 121 patients with hematologic diseases].
Jia L; Huang M; Liu WL; Zhang YC; Sun HY; Zhang DH; Deng JN; Zhou JF
Zhonghua Xue Ye Xue Za Zhi; 2008 Sep; 29(9):619-22. PubMed ID: 19175991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
